References of "Ethgen, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCan new information and communication technologies help in the management of osteoporosis ?
Slomian, Justine ULg; Appelboom, G; Ethgen, Olivier ULg et al

in Women's Health (2014), 10(3), 229-232

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailWhat do we know about the safety of corticosteroids in rheumatoid arthritis?
Ethgen, Olivier ULg; De Lemos Esteves, Frédéric ULg; Bruyère, Olivier ULg et al

in Current Medical Research & Opinion (2013), 29(9), 1147-60

Abstract Background: Clear information is still lacking on the safety of corticosteroids (GCs) therapy in RA despite six decades of clinical experience. Scope: We performed a literature search in Ovid ... [more ▼]

Abstract Background: Clear information is still lacking on the safety of corticosteroids (GCs) therapy in RA despite six decades of clinical experience. Scope: We performed a literature search in Ovid MEDLINE from January 2000 to December 2012. Our Population Intervention Comparator Outcomes (PICO) strategy search was: rheumatoid arthritis [Population], corticosteroids or glucocorticoids [Intervention], any comparison [Comparator], adverse effects [Outcome]. Studies were selected if they reported any measure of association between GCs intake and potential adverse effects in RA patients. Findings: We identified 1030 papers and selected for analysis 26 observational studies and six systematic reviews. The major side effects of GCs in RA are bone loss, risk of cardiovascular events and risk of infections as evidenced by large observational studies and not necessarily RCTs. Others associations were reported with herpes zoster, tuberculosis, hyperglycemia, cutaneous abnormalities, gastrointestinal perforation, respiratory infection and self-reported health problems such as cushingoid phenotype, ecchymosis, parchment-like skin, epistaxis, weight gain and sleep disturbance. Other potential adverse effects of GCs were studied but no association was found. These included psychological disorders, dermatophytosis, brain diseases, interstitial lung disease, memory deficit, metabolic syndrome, lymphoma, non-Hodgkin's lymphoma, renal function and cerebrovascular accidents. Most of the evidence emanates from observational researches and the inherent limitations of such data should be kept in mind. Conclusion: Recent observational data and systematic reviews suggest that GCs can lead to relatively alarming and burdensome side effects in RA. This is particularly true for patients who have longer term and higher dose therapies. GCs are largely used in RA and knowing their safety profile is essential to improve patients care. The design of new therapeutic strategies intended to minimize the daily dosing of GCs while conserving their beneficial effect should be encouraged. [less ▲]

Detailed reference viewed: 31 (17 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Neuprez, Audrey ULg et al

in Archives of Orthopaedic & Trauma Surgery (2012)

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis ... [more ▼]

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis. Methods Generic HRQOL was assessed with the shortform 36 (SF-36) and specific HRQOL with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results Out of the 39 subjects who have completed the 7 years of follow-up of this study, 22 (56.4 %) underwent a hip replacement surgery and the other 17 (43.6 %) a knee replacement. Six months after surgery, a significant improvement, compared to preoperative scores, was observed in two of the eight dimensions of the SF-36 (i.e. physical function and pain). The same dimensions, pain and physical function, at the same time, 6 months after surgery, measured by the WOMAC, showed a significant improvement as well, but there was no significant change in the stiffness score. From 6 months to the end of followup, changes in SF-36 scores showed a significant improvement in physical function (p = 0.008), role-physical (p = 0.004) and role-emotional (p = 0.01) while all scores of the WOMAC improved (p\0.001 for pain, p\0.001 for stiffness and p\0.01 for physical function). Conclusion The improvements observed in HRQOL at short term after surgery, are at least maintained over a 7-year follow-up period. [less ▲]

Detailed reference viewed: 44 (20 ULg)
Full Text
Peer Reviewed
See detailBiomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Miossec, P.; Verweij, C. L.; Klareskog, L. et al

in Annals of the Rheumatic Diseases (2011), 70(10), 1713-8

Rheumatoid arthritis (RA) is one of the most appropriate conditions for the application of personalised medicine as a high degree of heterogeneity has been recognised, which remains to be explained. Such ... [more ▼]

Rheumatoid arthritis (RA) is one of the most appropriate conditions for the application of personalised medicine as a high degree of heterogeneity has been recognised, which remains to be explained. Such heterogeneity is also reflected in the large number of treatment targets and options. A growing number of biologics as well as small molecules are already in use and there are promising new drugs in development. In order to make the best use of treatment options, both targeted and non-targeted biomarkers have to be identified and validated. To this aim, new rules are needed for the interaction between academia and industry under regulatory control. Setting up multi-centre biosample collections with clear definition of access, organising early, possibly non-committing discussions with regulatory authorities, and defining a clear route for the validation, qualification and registration of the biomarker-drug combination are some of the more critical areas where effective collaboration between the drug industry, academia and regulators is needed. [less ▲]

Detailed reference viewed: 67 (15 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement: a 7-year prospective study
Bruyère, Olivier ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Annals of the Rheumatic Diseases (2010, June), 69(Suppl.3), 469

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement : a 7-year prospective study
Bruyère, Olivier ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Osteoporosis International (2010, May), 21(Suppl.1), 26

Detailed reference viewed: 35 (12 ULg)
Full Text
Peer Reviewed
See detailPotential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications.
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Calcified Tissue International (2010), 86

This study aims to estimate the potential clinical and economic implications of therapeutic adherence to bisphosphonate therapy. A validated Markov microsimulation model was used to estimate the impact of ... [more ▼]

This study aims to estimate the potential clinical and economic implications of therapeutic adherence to bisphosphonate therapy. A validated Markov microsimulation model was used to estimate the impact of varying adherence to bisphosphonate therapy on outcomes (the number of fractures and the quality-adjusted life-years [QALYs]), health-care costs, and the cost-effectiveness of therapy compared with no treatment. Adherence was divided into persistence and compliance, and multiple scenarios were considered for both concepts. Analyses were performed for women aged 65 years with a bone mineral density T-score of -2.5. Health outcomes and the cost-effectiveness of therapy improved significantly with increasing compliance and/or persistence. In the case of real-world persistence and with a medical possession ratio (MPR; i.e., the number of doses taken divided by the number of doses prescribed) of 100%, the QALY gain and the number of fractures prevented represented only 48 and 42% of the values estimated assuming full persistence, respectively. These proportions fell to 27 and 23% with an MPR value of 80%. The costs per QALY gained, for branded bisphosphonates (and generic alendronate), were estimated at <euro>19,069 (<euro>4,871), <euro>32,278 (<euro>11,985), and <euro>64,052 (<euro>30,181) for MPR values of 100, 80, and 60%, respectively, assuming real-world persistence. These values were <euro>16,997 (<euro>2,215), <euro>24,401 (<euro>6,179), and <euro>51,750 (<euro>20,569), respectively, assuming full persistence. In conclusion, poor compliance and failure to persist with osteoporosis medications results not only in deteriorating health outcomes, but also in a decreased cost-effectiveness of drug therapy. Adherence therefore remains an important challenge for health-care professionals treating osteoporosis. [less ▲]

Detailed reference viewed: 42 (8 ULg)
Full Text
Peer Reviewed
See detailCost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence.
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Value in Health (2010), 13(4), 394-401

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis ... [more ▼]

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis. Methods: A validated Markov microsimulation model with a Belgian health-care payer perspective and a lifetime horizon was used to assess the cost per quality-adjusted life year (QALY) gained of the screening/treatment strategy compared with no intervention. Real-world adherence to alendronate therapy and full adherence over 5 years were both investigated. The real-world adherence scenario employed adherence data from published observational studies, and medication adherence was divided into persistence, compliance, and primary adherence. Uncertainty was investigated using one-way and probabilistic sensitivity analyses. Results: At 65 years of age, the costs per QALY gained because of the screening/treatment strategy versus no intervention are euro32,008 and euro16,918 in the real-world adherence and full adherence scenarios, respectively. The equivalent values are euro80,836 and euro40,462 at the age of 55 years, and they decrease to euro10,600 and euro1229 at the age of 75 years. Sensitivity analyses show that the presence of the upfront cost of case finding has a substantial role in the impact of medication adherence on cost-effectiveness. Conclusion: This study indicates that nonadherence with osteoporosis medications substantially increases the incremental cost-effectiveness ratio of osteoporosis screening strategies. All aspects of medication adherence (i.e., compliance, persistence, and primary adherence) should therefore be reported and included in pharmacoeconomic analyses, and especially in the presence of the upfront cost of case finding (such as screening cost). [less ▲]

Detailed reference viewed: 83 (22 ULg)
Full Text
Peer Reviewed
See detailClinical en economic implications of non-adherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2009, March), 20(S1), 16

Detailed reference viewed: 31 (6 ULg)
Full Text
Peer Reviewed
See detailDevelopment and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Value in Health (2009), 12(5), 687-696

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼]

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲]

Detailed reference viewed: 223 (32 ULg)
Full Text
Peer Reviewed
See detailImpact of medication non-compliance and non-persistence on pharmacoeconomic evaluations in osteoporosis
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Gathon, Henry-Jean ULg et al

in Osteoporosis International (2008, December), 19(S2), 282

Detailed reference viewed: 35 (13 ULg)
Full Text
Peer Reviewed
See detailCost-utility of calcium and vitamin D supplementation in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, December), 19(S2), 363

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailEfficiency of calcium and vitamin D supplementation in the management of osteoporosis
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 113

Detailed reference viewed: 26 (12 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of mass screening and targeted biphosphonates treatment in osteoporosis
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 117

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailCost-utility of strontium ranelate in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 6

Detailed reference viewed: 11 (5 ULg)